CardiolRx显示急性心肌炎患者的心脏严重恢复,支持了进一步的发展。 CardiolRx showed significant heart recovery in acute myocarditis patients, supporting further development.

心脏病治疗学报告称,在急性心肌炎中,ARCHER药物卡迪奥尔Rx的试验在第二阶段取得了积极结果,表明12周后左心血管重量比安慰剂(p=0.0117)减少9.2g(7%),表明反向改造和愈合。 Cardiol Therapeutics reported positive Phase II ARCHER trial results for its drug CardiolRx in acute myocarditis, showing a statistically significant 9.2g (7%) reduction in left-ventricular mass after 12 weeks versus placebo (p=0.0117), indicating reverse remodeling and healing. 支持磁共振举措的数据显示,主要发炎和纤维化标记减少,尽管主要的ECV终点和全球纵向压力在统计上并不显著。 Supporting MRI data showed reductions in key inflammatory and fibrotic markers, though the primary ECV endpoint and global longitudinal strain were not statistically significant. 安全性仍然良好。 Safety remained favorable. 这些结果增强了人们对该药物的抗炎和抗肺炎机制的信心,支持了目前第三阶段对经常的心肌炎和心脏衰竭的开发。 The results bolster confidence in the drug’s anti-inflammatory and anti-fibrotic mechanism, supporting ongoing Phase III development in recurrent pericarditis and heart failure. 分析人员维持了审计和调查处的评级,但由于更新估值和供资后稀释,将价格目标降低到7.80美元。 Analysts maintained a BUY rating but lowered the price target to $7.80 due to updated valuation and post-financing dilution.